APAC Acute Respiratory Distress Syndrome (ARDS) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 CAUSE LIFELINE CURVE 53
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.9 DBMR MARKET POSITION GRID 55
2.10 MARKET END USER COVERAGE GRID 56
2.11 VENDOR SHARE ANALYSIS 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PESTEL ANALYSIS 64
4.2 PORTERS FIVE FORCES 65
5 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: REGULATIONS 66
5.1 REGULATION IN U.S.: 66
5.2 REGULATION FOR VENTILATORS AND RESPIRATORY DEVICES AS PER FDA 67
5.3 REGULATION FOR THE USE OF VENTILATOR AND ANESTHESIA GAS MACHINE BREATHING CIRCUIT DEVICES 68
5.4 LABELING OF MODIFIED DEVICES 68
5.5 REGULATION IN EUROPE: 69
5.6 REGULATION IN INDIA: 70
5.7 REGULATION IN JAPAN: 71
6 REGIONAL SUMMARY 72
6.1 NORTH AMERICA REGION 72
6.2 EUROPE REGION 73
6.3 ASIA-PACIFIC 73
6.4 SOUTH AMERICA 74
6.5 MIDDLE EAST AND AFRICA 74
7 PIPELINE ANALYSIS 75
8 INSURANCE REIMBURSEMENT 77
8.1 CENTER FOR MEDICARE SERVICES (CMS)ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 77
8.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 78
8.3 ABBOTT CODING GUIDE FOR ECMO 78
8.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 79
8.5 CERN HEALTH INSURANCE SCHEME 79
8.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)  (MEDICARE & MEDICAID) 79
8.7 AMERICAN HOSPITAL ASSOCIATION 80
8.8 CONCLUSION 80
9 MARKET OVERVIEW 81
9.1 DRIVERS 83
9.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 83
9.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS 83
9.1.3 ACCELERATION IN PATIENT POOL OF COVID-19 WITH ARDS 84
9.1.4 RISING RATE OF AIR POLLUTION AND LIFESTYLE-RELATED DISEASES 84
9.1.5 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 85
9.2 RESTRAINTS 85
9.2.1 COMPLICATIONS ASSOCIATED WITH TREATMENTS 85
9.2.2 HIGH COST OF DEVICE AND TREATMENTS 86
9.2.3 LACK OF SKILLED WORKFORCE 86
9.3 OPPORTUNITIES 87
9.3.1 GROWING GERIATRIC POPULATION 87
9.3.2 RISING HEALTHCARE EXPENDITURE 88
9.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 88
9.3.4 IMPROVING AWARENESS REGARDING ARD SYNDROME 89

9.4 CHALLENGES 90
9.4.1 STRINGENT RULES & REGULATIONS 90
9.4.2 MULTIPLE CHALLENGES FACED BY ICU NURSES 90
10 IMPACT OF COVID-19 PANDEMIC ON THE ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 92
10.1 PRICE IMPACT 92
10.2 IMPACT ON DEMAND 93
10.3 IMPACT ON SUPPLY CHAIN 94
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS 94
10.5 CONCLUSION 95
11 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY TYPE 96
11.1 OVERVIEW 97
11.2 DIAGNOSIS 100
11.2.1 IMAGING TESTS 100
11.2.1.1 CHEST X-RAY 101
11.2.1.2 CT SCAN 101
11.2.1.3 ULTRASOUND 101
11.2.1.4 OTHERS 101
11.2.2 BLOOD TEST 101
11.2.3 RESPIRATORY RATE 101
11.2.4 SPO2 TEST 101
11.2.5 OTHERS 102
11.3 TREATMENT 102
11.3.1 MECHANICAL VENTILATION 103
11.3.1.1 HIGH-FLOW NASAL O2 103
11.3.1.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 103
11.3.1.3 CONTINOUS POSITIVE AIRWAY PRESSURE 103
11.3.1.4 PRONE POSITIVE VENTILATION 103
11.3.1.5 OTHERS 103
11.3.2 CORTICOSTEROIDS 104
11.3.2.1 METHYLPREDNISOLONE 104
11.3.2.2 DEXAMETHASONE 104
11.3.2.3 OTHERS 104

11.3.3 ANTIVIRAL MEDICATION 105
11.3.3.1 REMDESIVIR 105
11.3.3.2 COMBINATION DRUGS 105
11.3.3.3 OTHERS 105
11.3.4 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 105
11.3.5 TOCILIZUMAB 105
11.3.6 OTHERS 105
12 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY ROUTE OF ADMINISTRATION 106
12.1 OVERVIEW 107
12.2 PARENTERAL 110
12.2.1 INTRAVENOUS 110
12.2.2 INTRAMUSCULAR 110
12.3 ORAL 111
12.4 OTHERS 111
13 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY CAUSE 112
13.1 OVERVIEW 113
13.2 CORONAVIRUS DISEASE 2019 (COVID-19) 116
13.3 SEPSIS 116
13.4 INHALATION OF HARMFUL SUBSTANCES 117
13.5 SEVERE PNEUMONIA 117
13.6 OTHERS 118
14 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY END USER 119
14.1 OVERVIEW 120
14.2 HOSPITALS 123
14.3 SPECIALTY CLINICS 123
14.4 HOME HEALTHCARE 124
14.5 OTHERS 124
15 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY DISTRIBUTION CHANNEL 125
15.1 OVERVIEW 126
15.2 DIRECT TENDER 129
15.3 HOSPITAL PHARMACY 129
15.4 RETAIL PHARMACY 130
15.5 ONLINE PHARMACY 130
16 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET, BY REGION 131
16.1 ASIA-PACIFIC 132
16.1.1 JAPAN 141
16.1.2 CHINA 145
16.1.3 SOUTH KOREA 149
16.1.4 INDIA 153
16.1.5 AUSTRALIA 157
16.1.6 SINGAPORE 161
16.1.7 THAILAND 165
16.1.8 MALAYSIA 169
16.1.9 INDONESIA 173
16.1.10 PHILIPPINES 177
16.1.11 VIETNAM 181
16.1.12 REST OF ASIA-PACIFIC 185
17 ASIA PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET: COMPANY LANDSCAPE 186
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 186
18 SWOT ANALYSIS 187
19 COMPANY PROFILE 188
19.1 GILEAD SCIENCES INC. 188
19.1.1 COMPANY SNAPSHOT 188
19.1.2 REVENUS ANALYSIS 188
19.1.3 COMPANY SHARE ANALYSIS 189
19.1.4 PRODUCT PORTFOLIO 189
19.1.5 RECENT DEVELOPMENT 189
19.2 TERUMO CORPORATION 190
19.2.1 COMPANY SNAPSHOT 190
19.2.2 REVENUS ANALYSIS 190
19.2.3 COMPANY SHARE ANALYSIS 191
19.2.4 PRODUCT PORTFOLIO 191
19.2.5 RECENT DEVELOPMENT 191

19.3 GETINGE AB 192
19.3.1 COMPANY SNAPSHOT 192
19.3.2 REVENUS ANALYSIS 192
19.3.3 COMPANY SHARE ANALYSIS 193
19.3.4 PRODUCT PORTFOLIO 193
19.3.5 RECENT DEVELOPMENT 193
19.4 LIVANOVA PLC 194
19.4.1 COMPANY SNAPSHOT 194
19.4.2 REVENUE ANALYSIS 194
19.4.3 COMPANY SHARE ANALYSIS 195
19.4.4 PRODUCT PORTFOLIO 195
19.4.5 RECENT DEVELOPMENTS 195
19.5 MEDTRONIC 196
19.5.1 COMPANY SNAPSHOT 196
19.5.2 REVENUE ANALYSIS 196
19.5.3 COMPANY SHARE ANALYSIS 197
19.5.4 PRODUCT PORTFOLIO 197
19.5.5 RECENT DEVELOPMENTS 197
19.6 ALUNG TECHNOLOGIES, INC 198
19.6.1 COMPANY SNAPSHOT 198
19.6.2 PRODUCT PORTFOLIO 198
19.6.3 RECENT DEVELOPMENT 198
19.7 ARMSTRONG MEDICAL 199
19.7.1 COMPANY SNAPSHOT 199
19.7.2 PRODUCT PORTFOLIO 199
19.7.3 RECENT DEVELOPMENT 199
19.8 BESMED HEALTH BUSINESS CORP. 200
19.8.1 COMPANY SNAPSHOT 200
19.8.2 PRODUCT PORTFOLIO 200
19.8.3 RECENT DEVELOPMENTS 201
19.9 DRGERWERK AG & CO. KGAA 202
19.9.1 COMPANY SNAPSHOT 202
19.9.2 REVENUE ANALYSIS 202
19.9.3 PRODUCT PORTFOLIO 203
19.9.4 RECENT DEVELOPMENTS 203
19.10 EUROSETS 204
19.10.1 COMPANY SNAPSHOT 204
19.10.2 PRODUCT PORTFOLIO 204
19.10.3 RECENT DEVELOPMENT 204

19.11 F. HOFFMANN-LA ROCHE LTD 205
19.11.1 COMPANY SNAPSHOT 205
19.11.2 RECENT ANALYSIS 205
19.11.3 PRODUCT PORTFOLIO 206
19.11.4 RECENT DEVELOPMENTS 206
19.12 FISHER & PAYKEL HEALTHCARE LIMITED 207
19.12.1 COMPANY SNAPSHOT 207
19.12.2 REVENUE ANALYSIS 207
19.12.3 PRODUCT PORTFOLIO 208
19.12.4 RECENT DEVELOPMENTS 208
19.13 FRESENIUS SE & CO. KGAA 209
19.13.1 COMPANY SNAPSHOT 209
19.13.2 REVENUS ANALYSIS 209
19.13.3 PRODUCT PORTFOLIO 210
19.13.4 RECENT DEVELOPMENTS 210
19.14 HAMILTON MEDICAL 211
19.14.1 COMPANY SNAPSHOT 211
19.14.2 PRODUCT PORTFOLIO 211
19.14.3 RECENT DEVELOPMENT 211
19.15 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 212
19.15.1 COMPANY SNAPSHOT 212
19.15.2 PRODUCT PORTFOLIO 212
19.15.3 RECENT DEVELOPMENT 213
19.16 NIPRO 214
19.16.1 COMPANY SNAPSHOT 214
19.16.2 REVENUS ANALYSIS 214
19.16.3 PRODUCT PORTFOLIO 215
19.16.4 RECENT DEVELOPMENT 215
19.17 PFIZER INC. 216
19.17.1 COMPANY SNAPSHOT 216
19.17.2 REVENUS ANALYSIS 216
19.17.3 PRODUCT PORTFOLIO 217
19.17.4 RECENT DEVELOPMENT 217
19.18 RESMED 218
19.18.1 COMPANY SNAPSHOT 218
19.18.2 REVENUE ANALYSIS 218
19.18.3 PRODUCT PORTFOLIO 219
19.18.4 RECENT DEVELOPMENT 219

19.19 SMITHS MEDICAL 220
19.19.1 COMPANY SNAPSHOT 220
19.19.2 REVENUS ANALYSIS 220
19.19.3 PRODUCT PORTFOLIO 221
19.19.4 RECENT DEVELOPMENTS 221
19.20 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 222
19.20.1 COMPANY SNAPSHOT 222
19.20.2 PRODUCT PORTFOLIO 222
19.20.3 RECENT DEVELOPMENT 222
20 QUESTIONNAIRE 223
21 RELATED REPORTS 227